Drug Trial Radar · NCT06680947
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Dec 20, 2024
Primary completion
Feb 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
Conditions
- Asthma
Interventions
610Drug
Subcutaneously injection.
610Drug
Subcutaneously injection.
PlaceboDrug
Subcutaneously injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at week 52Time frame: Baseline (Day 1) and at week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.